{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-22-000028","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.703753+00:00","generated_at":"2026-06-24T02:08:25.965605+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024","bullets":["Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.","Cash and investments $160.9M as of June 30, 2022; expected to fund ops into Q3 2024.","First patient dosed in Phase 1 study of BDTX-1535; clinical update expected in 2023.","Appointed Sergey Yurasov as Chief Medical Officer in June 2022.","IND submission for BDTX-4933 targeted for H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-22-000028","json":"https://secwatch.observer/filing/0001701541-22-000028.json","markdown":"https://secwatch.observer/filing/0001701541-22-000028.md","text":"https://secwatch.observer/filing/0001701541-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/0001701541-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/bdtx-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:08:25.965605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}